Periodic Reporting for period 1 - BIOMATDB (Advanced Database for Biomaterials with Data Analysis and Visualisation Tools extended by a Marketplace with Digital Advisors)
Okres sprawozdawczy: 2022-06-01 do 2023-11-30
Biomaterials are synthetic or natural materials that can be used for medical purposes, such as artificial organs, prostheses, or tissue replacement. Due to the high demand for medical implants, the rising prevalence of cardiovascular diseases, and the increasing research on regenerative medicine, EU has supported biomaterial research for many years, resulting in numerous publications, patents, and clinical trials. However, one of the main challenges is to provide accessible and well-structured data of biomaterials for different stakeholders. Such data should include not only the metadata and properties of biomaterials, but also their biocompatibility, performance, and safety. The synthesis of this knowledge is difficult because of the large and diverse amount of data in the biomaterials’ domain.
Against this background, the BIOMATDB project aims to develop an advanced database (biomaterialdatabase.com) which will provide detailed information on the properties of biomaterials, based on the testing results from various research outputs. The database will have flexible tools for data analysis and visualisation, to help users search and select the best biomaterials for their needs. Additionaly, BIOMATDB project seeks to provide a web-optimised information marketplace (biomaterialmarketplace.com) with connected digital advisors to support companies, especially SMEs, to get market access and visibility for their biomaterial products. To this end, BIOMATDB aims to develop a label of biocompatibility that reflects biomaterial quality standards for application in a medical device or advanced therapy.
The BIOMATDB project will have a clear technological impact by organizing knowledge, facilitating information search, and enabling evidence-based selection of biomaterials for medical applications and device design. The project will also achieve an economic impact by creating a web-based marketplace for biomaterials, which will facilitate partnering activities for innovations and streamline cooperation between suppliers and demanders of biomaterials. The social impact of BIOMATDB will be realized through the increased public perception of the benefits of combining and exploiting heterogeneous data repositories with AI and machine learning algorithms for healthcare-related challenges. Finally, BIOMATDB will raise awareness of the importance of better tools and data to foster innovation and close the gap with other parts of the world in the field of biomaterials.
Against this background, the BIOMATDB project aims to develop an advanced database (biomaterialdatabase.com) which will provide detailed information on the properties of biomaterials, based on the testing results from various research outputs. The database will have flexible tools for data analysis and visualisation, to help users search and select the best biomaterials for their needs. Additionaly, BIOMATDB project seeks to provide a web-optimised information marketplace (biomaterialmarketplace.com) with connected digital advisors to support companies, especially SMEs, to get market access and visibility for their biomaterial products. To this end, BIOMATDB aims to develop a label of biocompatibility that reflects biomaterial quality standards for application in a medical device or advanced therapy.
The BIOMATDB project will have a clear technological impact by organizing knowledge, facilitating information search, and enabling evidence-based selection of biomaterials for medical applications and device design. The project will also achieve an economic impact by creating a web-based marketplace for biomaterials, which will facilitate partnering activities for innovations and streamline cooperation between suppliers and demanders of biomaterials. The social impact of BIOMATDB will be realized through the increased public perception of the benefits of combining and exploiting heterogeneous data repositories with AI and machine learning algorithms for healthcare-related challenges. Finally, BIOMATDB will raise awareness of the importance of better tools and data to foster innovation and close the gap with other parts of the world in the field of biomaterials.
The consortium achieved a significant progress in the frontend domain of the BIOMATDB Biomaterial database by creating a dashboard that provides a comprehensive overview of the biomaterial data. State-of-the-art natural language processing (NLP) tools were implemented to extract and process free-access sources related to biomaterials, which enrich the original data and improve the relevance of the information retrieved. A notable progress has been achieved towards the establishment of an BIOMATDB Biomaterial marketplace tailored for biomaterial suppliers as part of the BIOMATDB project. The consortium has implemented the primary infrastructure for the marketplace, which demonstrates its potential for the operational phase, and focuses on the upcoming testing and validation phases of the project.
To set the ground for the establishment of the envisioned biocompatibility label for biomaterials, which will indicate the quality standards of biomaterials for medical applications, the consortium proposed a standardized and contemporary definition of biocompatibility. To achieve this the project established a meticulous breakdown of biocompatibility evaluation stages, which will help to monitor the biocompatibility status of biomaterials. It carried out also a profound analysis of the ISO 10993, which is a standard for the preclinical assessment of biocompatibility, and collected the various evaluation techniques employed. To guarantee the seamless integration of the developed solutions, BIOMATDB implemented a Demonstration plan, which involves four phases. The initial demonstrations rely on internal input while the later ones on engaging external stakeholders. The demonstration plan aims also to validate the functionality, usability, security, efficiency, and accuracy of the developed solutions.
To set the ground for the establishment of the envisioned biocompatibility label for biomaterials, which will indicate the quality standards of biomaterials for medical applications, the consortium proposed a standardized and contemporary definition of biocompatibility. To achieve this the project established a meticulous breakdown of biocompatibility evaluation stages, which will help to monitor the biocompatibility status of biomaterials. It carried out also a profound analysis of the ISO 10993, which is a standard for the preclinical assessment of biocompatibility, and collected the various evaluation techniques employed. To guarantee the seamless integration of the developed solutions, BIOMATDB implemented a Demonstration plan, which involves four phases. The initial demonstrations rely on internal input while the later ones on engaging external stakeholders. The demonstration plan aims also to validate the functionality, usability, security, efficiency, and accuracy of the developed solutions.
The dashboard, which was implemented into the BIOMATDB Biomaterial database will help users such as researchers, policy makers and the general public to understand and visualize collected biomaterial data. By allowing a search of biomaterials based on various criteria and providing insights, the project will contribute to the advancement of science and innovation in the biomaterial’s domain. Through the provision of reliable and relevant data on the properties and performance of different biomaterials, the generated visualisations and representations will help doctors and patients choose the best suitable implant for their condition and needs, and avoid potential complications and adverse effects. Hence, the BIOMATDB Biomaterial database will increase the trust and satisfaction of doctors and patients with the medical implants by providing transparent and accessible information on the evidence and outcomes of using different biomaterials.
BIOMATDB consortium managed to establish a standardized and contemporary definition of biocompatibility as a part of the design and development of the planned biocompatibility label. This achievement will impact the harmonisation of the criteria and methods for evaluating the biological performance of biomaterials and medical devices across different academic and industrial fields and foster the innovation and development of new and improved biomaterials and medical devices that can meet the diverse and dynamic needs and preferences of the end users.
BIOMATDB consortium managed to establish a standardized and contemporary definition of biocompatibility as a part of the design and development of the planned biocompatibility label. This achievement will impact the harmonisation of the criteria and methods for evaluating the biological performance of biomaterials and medical devices across different academic and industrial fields and foster the innovation and development of new and improved biomaterials and medical devices that can meet the diverse and dynamic needs and preferences of the end users.